Showing results (1831-1840 of 1,863) with videos related to
Sort By:
Pageof 187
Gastroenterology|August 19, 2023
Hypoxia-Inducible Factor 1α Stabilization Restores Epigenetic Control of Nitric Oxide Synthase 1 Expression and Reverses Gastroparesis in Female Diabetic MiceFei Gao, Yujiro Hayashi, Siva Arumugam Saravanaperumal, et al.Journal of Korean Medical Science|August 17, 2021
Patient Perspectives and Preferences Regarding Gout and Gout Management: Impact on AdherenceMin Kyung Chung, Sung Soo Kim, Yun Hong Cheon, et al.Environmental Research|September 4, 2012
Korea National Survey for Environmental Pollutants in the human body 2008: 1-hydroxypyrene, 2-naphthol, and cotinine in urine of the Korean populationDonggeun Sul, Ryoungme Ahn, Hosub Im, et al.Blood Advances|December 4, 2024
Single-cell multiomics reveal divergent effects of DNMT3A- and TET2-mutant clonal hematopoiesis in inflammatory responseWazim Mohammed Ismail, Jenna A Fernandez, Moritz Binder, et al.Annals of the American Thoracic Society|February 13, 2016
Choice between Levofloxacin and Moxifloxacin and Multidrug-Resistant Tuberculosis Treatment OutcomesYoung Ae Kang, Tae Sun Shim, Won-Jung Koh, et al.The Korean Journal of Internal Medicine|January 29, 2019
Simplified disease activity changes in real-world practice: a nationwide observational study of seropositive rheumatoid arthritis patients with moderate-to-high disease activityKichul Shin, Sung Soo Kim, Sang-Heon Lee, et al.Nature Communications|May 19, 2018
Distinct epigenetic landscapes underlie the pathobiology of pancreatic cancer subtypesGwen Lomberk, Yuna Blum, Rémy Nicolle, et al.Clinical and Experimental Emergency Medicine|June 15, 2026
2025 Korean Guidelines for Cardiopulmonary Resuscitation: Part 4. Adult advanced life supportTae-Youn Kim, Gyo Jin Ahn, Kyoung-Chul Cha, et al.Lancet (London, England)|December 15, 2022
9 months of delamanid, linezolid, levofloxacin, and pyrazinamide versus conventional therapy for treatment of fluoroquinolone-sensitive multidrug-resistant tuberculosis (MDR-END): a multicentre, randomised, open-label phase 2/3 non-inferiority trial in South KoreaJeongha Mok, Myungsun Lee, Deog Kyeom Kim, et al.Antimicrobial Agents and Chemotherapy|December 6, 2021
Early Bactericidal Activity of Delpazolid (LCB01-0371) in Patients with Pulmonary TuberculosisJu Sang Kim, Yong-Hyun Kim, Sang Haak Lee, et al.Pageof 187